KANGMEI PHARMACEUTICAL CO

New leadership at Kangmei Pharmaceutical signals a governance overhaul, a Q1 2026 loss, and a shift toward high‑margin drug development and strategic M&A to turn around profitability.

Explore Kangmei Pharmaceutical’s leadership shift: interim chairman Ou Guoxiong, Guangyao Group’s influence, and the impact on governance, profitability, and investor confidence.

Regulatory probe, hidden debt, and legal battles plunge KANGMEI Pharmaceutical into crisis—why investors face mounting risk and how governance failures spark a market collapse.